Groundbreaking discoveries using MRI technology to help elevate population health outcomes

As we investigate new pathways, scalable, innovative MRI technology, powered by AI, will allow you to explore and discover new biomarkers which can lead to curing the most debilitating illnesses.
At a glance

From care to cure pathways

Enable deeper exploration of oncology, neurodegenerative & cardiovascular care pathways

A deeper understanding with AI

Advanced AI that enables precise diagnosis & personalized therapies

Enabling partnerships

Partnerships that translate research discovery into clinical adoption

Empowering providers to discover how to fight the most debilitating illnesses with the latest MRI technology

We are helping enable groundbreaking discoveries with a wide array of research-focused MRI technology. This technology is enabling deeper exploration of care pathways to better understand the world’s most debilitating diseases like cancer, neurodegenerative, cardiovascular and psychological disorders.

Our vision is to empower you with technology rooted in research collaborations along with continued innovation in AI and advanced imaging applications. Our ultimate goal is to help you discover new biomarkers that could lead to significant breakthroughs in your understanding of disease, accelerate the translation of research to clinical practice, and provide new hope for all patients.

$25.2T

Estimated global economic cost of cancers from 2020 to 2050¹

$612B+

Estimated socioeconomic burden due to neurological disorders²

500

GE HealthCare MR research projects underway globally³

34M+

Patients scanned using AIR™ Recon DL⁴

Providing hope for all patients through innovations in MRI technology

Explore groundbreaking technology that redefines MRI excellence and continues to push the boundaries in MRI.
From care to cure pathways

Enabling personalized oncology treatment with MRI

Our goal is to help you personalize cancer diagnosis, radiation therapy planning and treatment assessment for every patient. To achieve this, we can provide advanced functional and metabolic imaging information with SIGNA™ PET/MR AIR™⁵ and ODEN* (Oscillating Diffusion Encoding). Our AIR™ RT Suite solution is easy to set up and helps ensure the proper positioning of each patient. And the 32-channel AIR™ Open Coils provide patient comfort while delivering a high signal-to-noise ratio.

Exclusive AI applications like AIR™ Recon DL and MR Contour DL*, our auto-organ segmentation application that generates contours of at-risk organs, provides speed, consistency and accuracy, enabling the delivery of precise radiation therapy treatments.⁶

Explore neurology in a new way

Dedicated to exploring our most complex organ

We're committed to enhancing your understanding of the brain as well as enable the discovery and application of new treatment pathways for life-altering neurodegenerative diseases.

MotionFree Brain, available on SIGNA™ PET/MR AIR™, helps to significantly improve the visualization and quantitation of PET tracers that link to biochemicals associated with Alzheimer’s Disease, without any external devices.

Our ARIA imaging protocols help monitor and evaluate Amyloid Related Imaging Abnormalities for patients receiving beta-amyloid treatments for Alzheimer's Disease.

Unlock new insights into brain function with SIGNA™ MAGNUS*, our dedicated head-only MRI scanner. Push the boundaries of neurological research with the advanced capabilities of our SIGNA™ 7T⁷ scanner.

A deeper understanding with AI

Intelligent AI innovation for insightful imaging

As a leader in AI-enabled MRI solutions, SIGNA™ MR has introduced several groundbreaking AI-based applications to the market in just 7 years.

These applications include innovations in MRI protocol planning, acceleration, reconstruction and visualization. All designed to enhance the MRI experience for everyone. And this is only the beginning.

Enabling collaborations

Accelerating cutting-edge care through collaborations

With over 500 GE HealthCare MRI research studies underway globally, we actively collaborate with world-class healthcare providers and research institutions to help provide innovations that translate research discovery into clinical adoption, enabling leading-edge care.

By working closely with these organizations and collaborators, we are constantly building upon our collective strengths and pushing the boundaries of our shared knowledge. This infrastructure of excellence allows us all to help accelerate the development and clinical translation of advanced MRI technologies.

These collaborations help equip clinicians with technology to precisely diagnose and treat medical conditions, elevate theranostic care, reduce scan times and enhance the patient experience at each step of their journey.

More to explore

See what groundbreaking discoveries in MRI can do for you

Learn about our vision

See the future. Change the outcome.

SIGNA™ MR

Building a healthier future where healthcare has no limits

Effortless Imaging

Delivering effortless workflows and clinical excellence at the speed of life

Sustainable access

Providing sustainable solutions that make precision medicine available to all

Groundbreaking discoveries

Empowering providers to discover how to fight the most debilitating illnesses
References
1. Chen Simiao; Cao Zhong; Prettner Klaus et al, "Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050". Last modified: February 23, 2023. Https://jamanetwork.com/journals/jamaoncology/fullarticle/2801798
2. Álvaro Nuno Perez, Jose Suarez, Michel Le Barsh, "Sizing the brain. Segmentation and growth factors of the global neuroscience market". Last modified: February, 14,2023. Https://www2.deloitte.com/us/en/insights/industry/health-care/global-neuroscience-market-investment-report.html
3. Per CTMS data as of 10/1/2024.
4. Calculated from installed base data as of September 2024 with estimation of 20 scans per day, 5.5 working days a week and fully utilizing AIR™ Recon DL 4 weeks after delivery.
5. SIGNA™ PET/MR AIR™ is a premium configuration of SIGNA™ PET/MR. Not available for sale in all regions.
6. It is the responsibility of the user to verify the contours and user-defined labels for each organ at risk and correct the contours/labels as needed.
7. SIGNA™ 7T is a configuration of SIGNA™ 7.0T. SIGNA™ 7.0T is 510(k) cleared. Not yet CE Marked. Not available for sales in all regions.
*SIGNA™ MAGNUS and ODEN are 510(k) cleared with the FDA. Not yet CE Marked. Not available for sale in all regions.
**MR Contour DL is 510(k) pending with the U.S. FDA. Not CE Marked in Europe. Not available for sales in all regions.
Get in touch

Have a question about our groundbreaking MRI solutions? We would love to hear from you.

JB11066US